Biohaven Ltd. BHVN

BHVN Company Overview

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for neurological, neuropsychiatric, immunological, and rare diseases. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on neuroscience and immunology. Biohaven’s primary revenue drivers historically have included licensing arrangements, collaboration payments, and development-stage therapeutic programs, with current operations centered on advancing a diversified clinical pipeline following the 2022 acquisition of portions of its business by Pfizer Inc. The company is publicly traded on the New York Stock Exchange under the ticker BHVN.

Biohaven was originally founded in 2013 by Dr. Vlad Coric and developed a portfolio of calcitonin gene-related peptide (CGRP) therapies for migraine treatment. In 2022, Pfizer acquired Biohaven’s CGRP franchise, including the approved migraine therapy Nurtec ODT, while the remaining business continued independently as Biohaven Ltd. The post-transaction company retained and expanded a pipeline focused on glutamate modulation, ion channel therapeutics, antibody technologies, and protein degradation platforms. Biohaven’s strategic positioning is supported by its neuroscience expertise, broad intellectual property portfolio, and focus on high unmet medical need indications.